Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 483

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 483
---
 (“DRL”), dated August 3, 2021 (the “DRL
APA”), including an irrevocable, royalty-free, exclusive license to know-how and patents of DRL related to ELYXYB and necessary or used to exploit ELYXYB in the ELYXYB Territory. No cash consideration was
or will be payable to the Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include contingent sales and regulatory milestone payments and sales royalties. The Company is also obligated to make
quarterly royalty payments to DRL on net sales of ELYXYB in the ELYXYB Territory. In April 2023, the Company launched ELYXYB in the U.S. As of December 31, 2024 and 2023, the Company had ending balances of accrued royalty payables of $0.1 million
and $5.0 thousand, respectively, which was recorded as accrued expenses under current liabilities on the

F-20

consolidated balance sheets. During the years ended December 31, 2024 and 2023, the Company made royalty payments in the amount of $0.3 million and $26.0 thousand, respectively. As of December 31, 2024, no sales or regulatory milestone payments had been accrued as there were no potential milestones yet considered probable of achievement. 4. Fair Value Measurements The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands):

|                                          |     | December 31, 2024 |         |     |               |   |     |                  |   |     |                  |         |
|:-----------------------------------------|:----|:------------------|--------:|:----|:--------------|:--|:----|:-----------------|:--|:----|:-----------------|--------:|
|                                          |     | Balance           |         |     | Quoted Prices 
 in Active     
 Markets       
 (Level 1)     |   |     | Significant      
 Other            
 Observable       
 Inputs (Level 2) |   |     | Significant      
 Unobservable     
 Inputs (Level 3) |         |
| Liabilities                              |     |                   |         |     |               |   |     |                  |   |     |                  |         |
| Oramed Note                              |     | $                 |  12,